LacosamideThird Party Manufacturing in India

Lacosamide is a third-generation antiepileptic drug and a functionalized amino acid that exerts its anticonvulsant effect through a unique mechanism involving voltage-gated sodium channels. Unlike conventional sodium channel blocking antiepileptic drugs that affect fast inactivation, lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels. This process occurs when the sodium channel transitions from an open conducting state to a non-conducting inactivated state over a period of seconds rather than milliseconds. By shifting the slow inactivation curve to more hyperpolarized potentials and increasing the proportion of channels in the slow inactivated state, lacosamide stabilizes hyperexcitable neuronal membranes and inhibits sustained repetitive neuronal firing without affecting normal low-frequency neuronal activity. This selective action on slow inactivation is particularly effective at suppressing the high-frequency firing patterns characteristic of epileptic discharges. Lacosamide also binds to collapsin response mediator protein-2, a phosphoprotein involved in neuronal differentiation and axonal outgrowth, although the contribution of this interaction to its anticonvulsant effects remains under investigation. The drug does not exhibit affinity for GABA, NMDA, adenosine, or other neurotransmitter receptors and does not affect calcium or potassium channels, giving it a distinctive pharmacological profile among modern antiepileptic drugs.

Therapeutic Uses

Lacosamide is prescribed for the treatment of:

• Partial-Onset Seizures with or without Secondary Generalisation: Lacosamide is approved as monotherapy and adjunctive therapy in adults, adolescents, and children from 2 years of age with epilepsy experiencing focal seizures.
• Primary Generalised Tonic-Clonic Seizures: Lacosamide is indicated as adjunctive therapy in patients 4 years of age and older with idiopathic generalised epilepsy experiencing tonic-clonic seizures.
• Status Epilepticus: Off-label use of intravenous lacosamide has shown effectiveness in the management of refractory status epilepticus, particularly in patients who have not responded to benzodiazepines or other standard therapies.
• Diabetic Neuropathic Pain: Lacosamide has been investigated for painful diabetic neuropathy due to its sodium channel modulating effects, though this remains an off-label application.

Why Manufacturers Choose Lacosamide

Lacosamide is a high-growth molecule in the neurological segment, widely prescribed by neurologists and epileptologists worldwide. Available in 50 mg, 100 mg, 150 mg, and 200 mg tablet strengths, the product offers a complete dosing range for titration and maintenance therapy. Indian manufacturers benefit from lacosamide's expanding generic market as patents expire in regulated markets, creating significant export opportunities to the US, Europe, and emerging markets. The twice-daily dosing regimen and favourable drug interaction profile make it a preferred choice in combination therapy. Well-characterised manufacturing processes, established API supply chains, and consistent domestic demand through neurology prescription channels make lacosamide an attractive molecule for third party manufacturing and PCD franchise distribution in India. This makes Lacosamide one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.